alexa Abstract | Efficacy and safety of combined etanercept and iguratimod for active rheumatoid arthritis.

Biomedical Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


To study the efficacy and safety of combined etanercept and iguratimod in treatment of active rheumatoid arthritis. 45 patients were randomly divided into group A: etanercept+methotrexate (MTX) group; group B: etanercept+iguratimod group; and group C: iguratimod group. 45 patients with active rheumatoid arthritis treated at the hospital between July 2011 and July 2015 were divided into three groups, n = 15 in each group. Group A was treated with etanercept (subcutaneous injection at 25 mg twice weekly) in combination with MTX (initial dosage of 7.5 mg/week, and gradual increase of dosage to 15 mg/week from the fourth week). Group B was treated with etanercept (subcutaneous injection at 25 mg twice weekly) in combination with iguratimod (oral administration at 25 mg twice daily). Group C was treated with iguratimod alone (oral administration at 25 mg twice daily). Therapeutic efficacy was assessed according to the American College of Rheumatology (ACR) criteria. No statistically significant difference was not observed in the therapeutic efficacy between groups A and B, while the efficacy between groups A and C showed significant difference. After 52 weeks of treatment, ACR20 response rates were 69.12%, 63.45% and 50.24, respectively, for groups A, B and C. Group A had the response rate significantly higher than groups B and C (P<0.05). In group B, 2 patients experienced gastrointestinal discomfort. Etanercept combined with iguratimod has good safety and remarkable efficacy in treating active rheumatoid arthritis.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Yulan Sun Ping Wang Long Wang He Li Miao Li Yan Xu Wei Sun Lin Wang Yuhuan Yang Xiuling Zhang Lina Ma


Combined etanercept and iguratimod, Rheumatoid, Arthritis, Clinical trial, #

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version